Back to Journals » OncoTargets and Therapy » Volume 6

The Hedgehog inhibitor cyclopamine antagonizes chemoresistance of breast cancer cells

Authors Chai F, Zhou J, Chen C, Xie S, Chen X, Su P, Shi J

Received 22 July 2013

Accepted for publication 20 August 2013

Published 12 November 2013 Volume 2013:6 Pages 1643—1647

DOI https://doi.org/10.2147/OTT.S51914

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4


Feng Chai,1 Jiangang Zhou,1 Cheng Chen,1 Song Xie,2 Xiao Chen,1 Ping Su,3 Jun Shi3

1Oncology Department, 2General Surgery Department, 3Hematology Department, Zhejiang Xiaoshan Hospital, Hangzhou, People's Republic of China

Abstract: Chemoresistance of cancer cells has been a severe problem in multiple types of cancers. One possibility is to combine different drugs with chemotherapy for improved efficacy. Cyclopamine blocks Hedgehog signaling by antagonizing Smo function, which induces tumor apoptosis. Here, we show that the combined use of cyclopamine and paclitaxel (chemotherapy drugs) was able to induce breast cancer cell apoptosis both in vivo and in vitro. The results suggest that Hedgehog signaling is a prospective drug target for chemoresistant cancer cells.

Keywords: chemoresistance, Hedgehog signaling, cyclopamine, paclitaxel, cancer stem cell

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]